4Yuen MF,Fung J,Seto WK,et al.Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy. Antiviral Therapy . 2009
5Gauthier J,Bourne EJ,Lutz MW,et al.Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. The J of Infectious Diseases . 1999
7YF Liaw.On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future. Antiviral Therapy . 2009
8Keeffe EB,Dieterich DT,Han SHet al.A treatment algorithm for the management of chronic hepatitis B virus infection in the United States:2008 update. Clinics in Gastroenterology . 2008
9European Association for the Study of the Liver.EASL clinical practice guidelines:Management of chronic hepatitis B. Journal of Hepatology . 2009
10Y.F. Liaw,E. Gane,N. Leung.2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology . 2009
二级参考文献36
1Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
8Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association.肝衰竭诊疗指南[J].中华肝脏病杂志,2006,14(9):643-646. 被引量：830
